CALQUENCE

USDailyMed:Acalabrutinib AU:C L01EL02(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-only 4-{8-amino-3-[(2S)-1-(2-butynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide 1420477-60-6 71226662 DB11703 36764951 I42748ELQW D10893 CHEBI:167707 ChEMBL3707348 XQQ (PDBe,RCSB PDB) Interactive image CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12 InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1Key:WDENQIQQYWYTPO-IBGZPJMESA-N Acalabrutinib, sold under the brand nameCalquence, is ananti-cancer medicationused to treat various types ofnon-Hodgkin lymphoma, includingmantle cell lymphomaandchronic lymphocytic leukemia/small lymphocytic lymphoma.It may be used both in relapsed as well as in treatment-naive settings. Common side effects include headaches, feeling tired,low red blood cells,low platelets, andlow white blood cells.It is a second generationBruton's tyrosine kinaseinhibitor.Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow.By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in chronic lymphocytic leukemia, thereby delaying progression of the cancer. Acalabrutinib was approved for medical use in the United States in 2017,and in the European Union in November 2020.